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ABSTRACT: One-third of the world’s population carries Mycobacterium tuber-
culosis (Mtb), the infectious agent that causes tuberculosis (TB), and every 17 s
someone dies of TB. After infection, Mtb can live dormant for decades in a
granuloma structure arising from the host immune response, and cholesterol is
important for this persistence of Mtb. Current treatments require long-duration
drug regimens with many associated toxicities, which are compounded by the high
doses required. We phenotypically screened 35 6-azasteroid analogues against Mtb
and found that, at low micromolar concentrations, a subset of the analogues
sensitized Mtb to multiple TB drugs. Two analogues were selected for further study
to characterize the bactericidal activity of bedaquiline and isoniazid under normoxic
and low-oxygen conditions. These two 6-azasteroids showed strong synergy with
bedaquiline (fractional inhibitory concentration index = 0.21, bedaquiline minimal
inhibitory concentration = 16 nM at 1 μM 6-azasteroid). The rate at which
spontaneous resistance to one of the 6-azasteroids arose in the presence of bedaquiline was approximately 10−9, and the 6-
azasteroid-resistant mutants retained their isoniazid and bedaquiline sensitivity. Genes in the cholesterol-regulated Mce3R
regulon were required for 6-azasteroid activity, whereas genes in the cholesterol catabolism pathway were not. Expression of a
subset of Mce3R genes was down-regulated upon 6-azasteroid treatment. The Mce3R regulon is implicated in stress resistance
and is absent in saprophytic mycobacteria. This regulon encodes a cholesterol-regulated stress-resistance pathway that we
conclude is important for pathogenesis and contributes to drug tolerance, and this pathway is vulnerable to small-molecule
targeting in live mycobacteria.
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Cholesterol metabolism plays an important role in thepersistence, virulence, and intracellular survival of
Mycobacterium tuberculosis (Mtb).1−5 Mtb is able to survive
and replicate inside macrophages6 by utilizing host-derived
nutrients, including cholesterol.1−3,7 Mtb catabolism of
cholesterol provides a source of acetyl-coenzyme A (CoA),
pyruvate, and propionyl-CoA, which can be utilized for energy
production and as lipid precursors.8 Catabolism proceeds
through β-oxidation of the side chain and oxidative cleavage of
the sterol rings.9 Comparison of transcriptional profiles of Mtb
cultured with and without cholesterol identified over 200 genes
that are regulated by cholesterol.2 At least 52 cholesterol-
regulated genes are clustered within the Mtb genome and
encode the enzymes needed for catabolism.2,8 Two TetR
family regulators, KstR1 and KstR2, control transcription of
the majority of these catabolism genes10,11 and are derepressed
by CoA metabolites of the catabolism pathway.12,13
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Owing to the large number of potential targets in the Mtb
cholesterol metabolism pathway, the protein target that would
be the most vulnerable to inhibition is not clear.14 Therefore,
we undertook whole-cell phenotypic screening to identify
inhibitors of Mtb growth. We reasoned that use of a steroid
scaffold would bias the screen to target cholesterol metabolism.
We further sought a scaffold with pharmacokinetic properties
that would be advantageous for future in vivo experimentation.
For this purpose, we chose the 6-azasteroid scaffold (Figure
1). The 6-azasteroids were developed by Glaxo-Wellcome as
part of a 5α-reductase inhibitor program for treatment of
benign prostatic hyperplasia, but they were subsequently
abandoned in favor of 4-azasteroids.15−18 Several 6-azasteroids
were found to be orally bioavailable in rats, dogs, or both and
to have low in vivo toxicity.16 Because of the pharmacokinetic
properties of 6-azasteroids and their structural similarity to
cholesterol, we chose to screen them as possible inhibitors of
cholesterol metabolism in Mtb.
Previously, we demonstrated that 6-azasteroids with a large,
hydrophobic R1 side chain and an unsubstituted N6 atom (e.g.,
4a, Figure 1) are competitive inhibitors of 3β-hydroxysteroid
dehydrogenase.19 However, because this enzyme is not
essential for Mtb survival in the mouse or guinea pig models
of infection, its relevance as a drug target was questionable.20
We reasoned that other enzymes in the Mtb cholesterol
metabolism pathway might also be susceptible to inhibition by
compounds with the 6-azasteroid scaffold. In the present study,
we identified several 6-azasteroids with antimycobacterial
activity that improve the activity of existing anti-TB drugs,
and we established a relationship between activity and side-
chain structure. By investigating the mechanism of action and
the target of two of the active 6-azasteroids in Mtb, we
identified a connection between stress resistance and
cholesterol-regulated genes that reside outside the cholesterol
catabolic pathway. The inhibitors described herein offer a
strategy for combating innate drug tolerance in Mtb and
highlight the complex role of cholesterol-regulated genes in
Mtb infection.
■ RESULTS
6-Azasteroids Were Prepared from Intermediate 1.
Following a previously established synthetic route,15−18 we
prepared a library of 6-azasteroids from key intermediate 1
(Figure 1), which was prepared on a 500 g scale. Briefly,
hydrolysis of the methyl ester group of 1 followed by activation
of the resulting carboxylic acid and substitution reactions with
various primary amines provided amides 3 with more than 20
different substituents at R1. Subsequent deprotection of the
ring nitrogen provided compounds 4a−4v. Alkylation of 4a or
4b at N6 provided compounds 5a−7a and 6b. Treatment of 4a
with an excess of sodium hydride and iodomethane yielded 8a,
which has a methyl group both on the ring nitrogen and at C2.
All compounds were purified by column chromatography
before testing. Yields from intermediate 1 ranged from 60% to
90%.
6-Azasteroids Inhibit Mtb Growth in Combination
with Isoniazid. We initially screened the synthesized 6-
azasteroids (Figure 1) to determine their minimal inhibitory
concentrations (MICs) in a Mtb growth assay. As a carbon
source, we used cholesterol solubilized in tyloxapol detergent
Figure 1. Structures and synthesis of 6-azasteroids. Key intermediate 1 was prepared as described in the literature16−18 and subjected to further
elaboration as shown.
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micelles to ensure that we could detect activity against the
cholesterol catabolism pathway. The 6-azasteroid concen-
trations were varied from 0.15 to 40 μM. We were unable to
obtain accurate MICs, but we estimated the values to exceed
40 μM for the compounds that showed at least some activity.
Despite the lack of MICs for most of the 6-azasteroids, we
recognized that they might show synergistic activity when
combined with isoniazid (INH), a frontline TB drug.
Therefore, we screened for inhibition of Mtb growth at a
fixed concentration of 6-azasteroid (20 μM) while varying the
INH concentration. The potentiation potency was recorded as
a fold change of the INH MIC. Of the 35 6-azasteroids tested
in combination with INH, seven (4a, 4d, 5a−8a, and 3c)
improved the INH MIC at least 16-fold (Figure 2). In
addition, compound 6b showed moderate potentiation with a
4-fold decrease in the INH MIC. We also tested two 4-
azasteroids, finasteride and dutasteride, which inhibit human
5α-reductase and are FDA-approved for treatment of benign
prostatic hyperplasia. Neither of the 4-azasteroids showed
inhibitory activity, either alone or in combination with INH.
Clear Structure−Activity Relationship Was Observed
for the 6-Azasteroids. Among the compounds with R2 = H
(4), an aniline side chain at R1 was required. Compounds with
side chains derived from aliphatic amines (4n, 4o, 4p, 4r, 4s)
or aliphatic amines linked to aromatic groups (4m, 4q, 4t)
were inactive. Furthermore, compounds with aniline side
chains bearing a single substituent (4e, 4f, 4g), compounds
with aniline side chains bearing polar substituents (4b, 4c, 4h,
4i, 4j, 4k, 4l), and compounds with pyridyl-based side chains
(4u and 4v) were inactive. Only 4a and 4d, the (2,5-di-t-
butyl)phenyl and the (3,5-di-t-butyl)phenyl compounds,
improved INH activity. The activity of parent compound 4a
was retained upon installation of an alkyl R2 substituent on the
ring nitrogen (5a, 6a, 7a). Interestingly, moderate potentiation
was observed upon conversion of the inactive 2-t-butyl-5-
trifluoromethylaniline-derived compound 4b to N-propyl
derivative 6b. Likewise, compound 3c, which has a t-
butyloxycarbamate-protected ring nitrogen, was active, whereas
the corresponding unprotected compound (4c) was not. Thus,
derivatization of the aza ring nitrogen was well tolerated and, in
some cases, could convert inactive compounds into potentia-
tors of INH activity.
6-Azasteroid Activity Is Not Specific for Cholesterol
Catabolism. Next, we assessed the specificity of the 6-
azasteroid scaffold for cholesterol catabolism. We found that
when glycerol was used as the carbon source, the seven active
6-azasteroids retained their ability to improve the efficacy of
INH. As a negative control, we tested compound 4g, which
was inactive with cholesterol as the carbon source, and found it
remained inactive in glycerol (Figure S1). Thus, the activity of
6-azasteroids was not carbon-source specific.
Two of the active compounds, 4a and 6a, were selected for
further study. Their effect on the rates of CDC1551 Mtb
growth was monitored by optical density (OD). As expected
from our initial MIC screen, 10 μM 4a or 6a did not inhibit the
growth of Mtb on glycerol as a carbon source over the course
of 15 days (Figure 3A).
6-Azasteroids Improve the Activity of Other TB
Drugs and Drug Candidates. Compounds 4a and 6a
were tested as potentiators of the following additional TB
drugs and drug candidates: rifampin, pretomanid, bedaquiline
(BDQ), clofazimine, pyrazinamide, moxifloxacin, linezolid, and
ethionamide. We found that these two 6-azasteroids improved
the activity of at least five of the TB drugs in vitro: rifampin,
pretomanid, BDQ, pyrazinamide, and ethionamide (Tables 1
and S1A). The 6-azasteroids did not appear to improve the
activity of clofazimine, linezolid, or moxifloxacin. BDQ, in
addition to INH, was selected for further study because it is
used for the treatment of multidrug-resistant Mtb infection.
6-Azasteroids Show Synergism with INH or BDQ.
Using the H37Rv(mlux) strain, we carried out a checkerboard
growth-inhibition assay at various 4a or 6a and INH or BDQ
concentrations. As expected, neither 10 nor 20 μM 4a
inhibited the growth of H37Rv(mlux) (Figure 3B). A sub-
MIC concentration of INH (0.032 μM) also failed to inhibit
growth. However, when Mtb was treated simultaneously with
20 μM 4a and 0.032 μM INH, growth was inhibited. Similarly,
at a low concentration (4 μM), BDQ alone inhibited growth
by approximately 50%. Importantly, when BDQ was used in
combination with 4a, complete inhibition was observed.
Likewise, combinations of 6a and 0.032 μM INH or 4 μM
Figure 2. 6-Azasteroids improve the efficacy of INH. CDC1551Mtb in 7H9 medium with cholesterol as a carbon source was incubated with 20 μM
6-azasteroid, finasteride, dutasteride, or DMSO control and varying concentrations of INH (2-fold dilutions) for 14 days at 37 °C. The INH
concentration at which no growth occurred was recorded as the MIC. Results are shown as the ratio of the INH MIC in the presence of azasteroid
or DMSO to the MIC of INH alone (0.2−0.4 μM). A ratio of 0.5−1 is considered to indicate no change in the INH MIC. The data shown are
representative of at least two experiments.
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BDQ resulted in complete inhibition (Figure 3C). Growth
readings at day 9 were used to prepare an isobolographic plot
for INH and 6-azasteroid (Figure S2). Although an accurate 6-
azasteroid MIC could not be determined from the plots, the
combinations of 4a or 6a and INH were clearly synergistic.
6-Azasteroids Improve Bactericidal Activity. Combin-
ing 6a with BDQ (1.8 μM) improved the bactericidal activity
of BDQ. Specifically, the combination of 10 μM 6a and BDQ
resulted in a 2 log10 CFU improvement in bacterial kill at day 7
of treatment. However, the rate of bacterial kill by BDQ was
not increased, as evidence by the 2-day time points (Figures
3D and S3A). The combination of 4a and INH was also
bactericidal (Figure S3B).
6-Azasteroids Are More Potent under Low-Oxygen
Conditions than under Normoxic Conditions. We also
conducted a checkerboard low-oxygen recovery assay (LORA)
of H37Rv(mlux) growth inhibition by 4a or 6a and INH or
BDQ at various concentrations (Figure 4). Both 4a and 6a
were active in the LORA, showing MICs of 11 and 13 μM,
respectively. Although INH was not active under low-oxygen
conditions (MIC ≈ 400 μM), treatment with INH plus 4a or
6a reduced the MIC at least 2-fold (Figure 4A). The LORA
fractional inhibitory concentration (FIC) indices for INH/4a
and INH/6a were 0.75 and 0.69, respectively. BDQ had an
MIC of 160 nM in the LORA. Compound 4a or 6a improved
BDQ activity in the LORA (Figure 4B). At 4.4 μM, 4a reduced
the BDQ MIC approximately 50-fold (to 3 nM), and 6a
reduced the BDQ MIC to 23 nM. The FIC index for both
BDQ/4a and BDQ/6a was 0.21, indicating strong synergy.
6-Azasteroids Improve the Bactericidal Activity of
BDQ under Low-Oxygen Conditions. The bactericidal
activities of 4a and 6a were determined under low-oxygen
conditions. The minimum bactericidal concentration of 4a was
80 μM and that of 6a was higher than 80 μM (80% kill). To
assess the bactericidal activity of combinations of 6-azasteroids
and BDQ, we performed a time-kill assay with 10 μM 4a or 6a
in combination with BDQ at concentrations below the
minimum bactericidal concentration (Figure 4C). At day 10
Figure 3. Azasteroids 4a and 6a inhibit Mtb growth and are bactericidal in combination with INH or BDQ. (A) CDC1551 Mtb was cultured in
7H9 medium with glycerol as a carbon source and was diluted to an OD (600 nm) of 0.2. These cultures were incubated with 10 μM 4a or 6a or
with DMSO as a control (two replicates), and the growth of Mtb was monitored by OD (600 nm) for 15 days. Data are representative of at least
two experiments. (B) H37Rv(mlux) Mtb was cultured in 7H9/glycerol medium and diluted to approximately 5−10 RLU per well. These cultures
were incubated with INH, BDQ, and/or 4a at the indicated concentrations or with DMSO as a control, and the growth of Mtb was monitored by
autoluminescence for 9 days. (C) H37Rv(mlux) Mtb was cultured in 7H9/glycerol medium and diluted to approximately 5−10 RLU per well.
These cultures were incubated with INH, BDQ, and/or 6a at the indicated concentrations or with DMSO as a control, and the growth of Mtb was
monitored by autoluminescence for 9 days. (D) CDC1551 Mtb was cultured in 7H9/glycerol medium and diluted to an OD (600 nm) of
approximately 0.002. These cultures were incubated with BDQ and/or 6a at the indicated concentrations or with DMSO as a control. After 2 or 7
days, the cultures were diluted, and the CFUs were determined by serial dilution onto agar plates. Error bars in panels B−D indicate SDs (n = 2).
The limit of detection is 10 CFU/mL.
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of treatment, the combination of 10 μM 4a and 0.15 μM BDQ
resulted in a 3.2 log10 CFU reduction in bacterial kill relative to
that in a no-drug control group. In addition, this same
combination (10 μM 4a plus 0.15 μM BDQ) resulted in a 1.4
log10 CFU reduction in bacterial kill at day 10 relative to that
in the BDQ-only group at a slightly higher BDQ concentration
(0.25 μM); that is, 10 μM 4a plus 0.15 μM BDQ was more
potent than 1−0.25 μM BDQ alone (Figure 4C).
6-Azasteroids Retain Potentiation Activity in Choles-
terol Catabolism Mutants. Because 6-azasteroids are
cholesterol analogues, we determined whether the cholesterol
catabolism pathway was required for azasteroid activity. For
this purpose, we tested the activity of 6-azasteroids in
combination with INH in mutant Mtb strains with disrupted
cholesterol catabolism genes. Specifically, we selected strains
with mutations in fadA5, chsE4 (fadE26), fadE31, and fadE33
(the transcription of which is repressed by the two main
transcriptional regulators of cholesterol catabolism, KstR1 and
KstR2)10,11 and in hsd (which encodes the first enzyme in the
pathway).21 KstR1 regulates the transcription of genes
encoding side-chain- and A/B-ring-degrading enzymes, where-
as KstR2 regulates the transcription of genes encoding C/D-
ring-degrading enzymes. These two regulators are derepressed
by CoA metabolites in the pathway.12,13 We found that none of
these five genes were required for 4a to improve INH activity
against Mtb grown with either cholesterol or glycerol as the
carbon source (Tables 2 and S1B).
Mce3R Regulon Is Required for Potentiation of INH
by 6-Azasteroids. Previously, we discovered that the Mce3R
regulon encodes FadE17-FadE18, an unusual heterotetrameric
acyl-CoA dehydrogenase that is associated with cholesterol
metabolism.22 Moreover, Mce3R regulates the mel2 operon,
which is implicated inMtb persistence in macrophages23 and in
resistance to oxidative stress24 that is associated with lipid
metabolism.25,26 The regulon is derepressed upon treatment
with cholesterol, most likely by a cholesterol metabolite,2 and
expression of the regulon is up-regulated during hypoxia and in
the stationary phase.27 We found that azasteroid 4a no longer
improved INH activity when tested against Mtb Mce3R
regulon mutants fadE18, melF, and melH (Table 2), and this
loss of activity was independent of carbon source.
The cholesterol catabolism pathway regulated by KstR1 and
KstR2 is found in both saprophytic and pathogenic
mycobacteria.28 In contrast, the Mce3R regulon is conserved
in M. marinum and Mtb but not in other pathogens (e.g.,
M. avium) or in saprophytic mycobacteria (e.g., M. smegmatis).
In results consistent with our mutant potentiation data, we
found that 6-azasteroid 4a did not improve INH or BDQ
activity when tested against M. smegmatis or M. avium grown
with glycerol as a carbon source (Table 2). However,
inhibition of M. marinum growth by BDQ and INH was
increased by addition of 4a.
Spontaneous Resistance to 6a Is Mce3R Independ-
ent. We examined the frequency with which spontaneous
resistance to one of the azasteroids arose (Table 3).
Specifically, resistant mutants were raised against 6a alone
and in combination with BDQ. The reported frequency of in
vitro resistance to 20 μM BDQ ranges from 9 × 10−9 to 5 ×
10−7 mutations per cell division, and mutations arise
predominately in the atpE gene.29 We found similar
frequencies of BDQ resistance in this study. The frequencies
of resistant mutant formation upon treatment with 6a in
combination with BDQ were comparable to the frequencies of
BDQ resistance. Treatment with 6a alone resulted in an
Table 1. 6-Azasteroids 4a and 6a Improve the Efficacy of Multiple TB Drugsa
aCDC1551 Mtb or H37Rv(mlux) Mtb in 7H9 medium with glycerol as a carbon source was incubated at 37 °C with 20 μM 4a or 6a or with
DMSO control and one of the listed drugs (2-fold dilution) at various concentrations for 14 days (CDC1551) or 6 days (H37Rv(mlux)). The drug
concentration at which no growth occurred was recorded as the drug MIC. The ratio of the drug MIC in the presence of azasteroid to the MIC of
the drug alone was determined. Ratios of 0.0625−0.125 are indicated by green shading and are considered to reflect potentiation. Ratios of 0.5−1
are indicated by red shading and are considered to reflect no change in MIC. Data are representative of at least two independent biological replicate
experiments, which were performed in technical triplicate. MIC values are listed in Table S1A. bValues in this column are MICs for CDC1551 Mtb
except for clofazimine. cExperiment performed only with CDC1551 Mtb. dExperiment performed only with H37Rv(mlux) Mtb.
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approximately 5−10-fold higher frequency of resistance. All the
resistant mutants that formed upon treatment of 6a alone or in
combination with BDQ had significant alterations in colony
morphology. The wild-type colonies were thick, rough,
irregular, and yellow, whereas the mutant colonies were thin,
small, round, and almost transparent (Figure S4). Twenty
mutants were selected, and six of these grew in liquid culture.
The mutant colonies unable to grow in liquid culture were
restreaked on agar plates, and one more mutant grew. All the
resistant mutants grew slowly in liquid culture or on agar
plates. The 6a, BDQ, and INH MICs against these seven
mutants were determined (Figure S1C). Against three of the
mutants (ASR1, ASR4, and ASR5), the MIC of 6a increased
more than 4-fold with respect to the MIC against WT-
CDC1551, whereas a 2−4-fold increase was observed for the
remainder of the mutants. The INH and BDQ MICs against all
the 6a-selected mutants were unchanged (1−2-fold increase)
compared to their MICs against WT-CDC1551.
DNA from six of the resistant mutants was sequenced. Only
three mutants (ASR1, ASR2, and ASR3) produced high-quality
data; the DNA from the other three mutants was highly
fragmented. Twenty-nine nonsynonymous single nucleotide
polymorphisms (SNPs), occurring in 25 genes, were identified
and confirmed by at least 10 Illumina reads (Figure S5). Of the
25 genes, 6 belong to the PE/PPE family and 3 encode
enzymes involved in PDIM biosynthesis.
Because mutant ASR2 showed no significant increase in the
6a MIC, we focused on analyzing mutants ASR1 and ASR3, in
which we identified, respectively, 21 and 11 nonsynonymous
SNPs, with 3 SNPs that were identical in both mutants. A stop
gain occurred at S154 in Rv2940c, which encodes a
mycocerosic acid synthase involved in PDIM biosynthesis. In
addition, we identified a frameshift insertion at P188 in
Rv3467, a nonessential gene, and a recombination of PPE19.
No Mce3R gene mutations were identified in the resistant
mutants.
Figure 4. 6-Azasteroids and INH or BDQ interact under low-oxygen conditions. Isobolographic analysis of codrug LORA MIC in H37Rv(mlux)
Mtb: (A) INH and 4a or 6a and (B) BDQ and 4a or 6a. The lines connecting 400 μM INH or 0.21 μM BDQ and 13 μM 4a or 6a denote lines of
additivity. H37Rv(mlux)Mtb was cultured and diluted to approximately 5−10 RLU per well. These cultures were incubated with INH or BDQ and
4a or 6a at a checkerboard of concentrations (3-fold dilutions) or with DMSO as a control under hypoxic conditions for 10 days. The RLU values
for H37Rv(mlux) Mtb after 28 h of normoxic recovery were recorded. The drug concentrations in wells with at least 90% inhibition of growth
relative to that in the no-drug control are plotted. Plotted values are averages (n = 3). (C) H37Rv(mlux)Mtb was cultured at approximately 1 × 105
CFU/mL. These cultures were incubated with BDQ, 4a (10 μM), or 6a (10 μM), alone or in combination, at the indicated concentrations under
hypoxic conditions for 10 days. The cultures were diluted, and CFUs were determined by serial dilution onto agar plates. Plotted values are
averages with SDs (n = 3); *p < 0.05. The limit of detection is 10 CFU/mL.
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As for individual nonsynonymous mutations, we determined
that ASR1 carried a nonsynonymous SNP in guaB3 (Rv3410c),
which is an essential gene annotated as an inosine-5′-
monophosphate dehydrogenase (Figure S5). However,
GuaB3 does not perform this dehydrogenase enzymatic
function.30 The guaB3 gene resides in a three-gene operon
Rv3409c-guaB3-guaB2, and Rv3409c is required for bacterial
survival and growth in macrophages.31 We also identified
frameshift deletions in Rv0678, Rv2552c, and Rv3267 from
ASR1. These genes are involved in the regulation of a cell
efflux system, aromatic amino acid synthesis, and cell-wall
synthesis, respectively. A frameshift deletion was also identified
in Rv0204c from ASR3. The disruptions in genes involved in
mycobacterial cell-wall biosynthesis are consistent with the
phenotypic changes in colony morphology that we observed.
6-Azasteroids Suppress the Transcription of Mtb
Stress-Response Genes Including the Mce3R Regulon.
RNA-seq gene expression profiles of the wild-type CDC1551
Mtb and the resistant mutants ASR1 and ASR2 were generated
after 6 h of exposure to 4a or 6a. Upon treatment of the wild-
type with 4a or 6a, genes involved in lipid metabolism, cell-wall
synthesis and cell processes, PE/PPE, and information
pathways (TubercuList functional classes) were generally
down-regulated (>2-fold). The global expression profiles for
4a and 6a treatment were like the profile for BDQ treatment,
with >80% of the genes that were down-regulated by BDQ
(>1.5-fold) also being down-regulated (>1.5-fold) by 4a.32 In
the absence of any of the test compounds, resistant mutants
ASR1 and ASR2 had a common set of 49 up-regulated (>2-
fold) genes, including stress-response genes regulated by DosR,
PhoP/R, MprA, Crp, and WhiB3.33
In addition to the observed general response to drug
treatment, six sets of genes that appeared to be specific to the
6-azasteroid mechanism of action were up- or down-regulated
by treatment of wild-type CDC1551 Mtb with 4a or 6a
(Figures 5 and S6). The magnitude of differential expression of
these specific genes in response to treatment with 4a or 6a was
much lower in ASR1 than in the wild-type, a result that is
consistent with the increased drug MIC.
In the wild-type CDC1551 Mtb, the KstR1 and KstR2
regulon genes that encode cholesterol catabolism enzymes
were either up-regulated or unaffected (Figure 5). In contrast,
KstR1 genes not directly related to cholesterol catabolism were
greatly down-regulated (up to 25-fold, not shown). Addition-
ally, KstR1-regulated genes in the mce4 operon, which encodes
the cholesterol transport system, were down-regulated by 4a or
6a. Genes in the mce1R operon, which is associated with
mycolic acid transport, and in the mel1 operon, which encodes
putative membrane protein and transglutaminases thought to
be important for infection,23 were greatly down-regulated (>5-
fold). In the wild-type, the Mce3R-regulated echA13-fadE17-
fadE18 operon was down-regulated by treatment with 4a or 6a,
whereas the other two Mce3R-regulated operons were
unaffected. In addition, guaB2, which is in the Rv3409c-
guaB3-guaB2 operon, was up-regulated by 4a or 6a (Table S4).
Gene expression of representative genes from Mce3R, KstR1,
and KstR2 regulons and mel1 operon in Mtb CDC1551
exposed to 4a was confirmed by qRT-PCR (Figure S6).
■ DISCUSSION
We tested 37 azasteroids in MIC assays and identified a set of
eight 6-azasteroids that clearly sensitized Mtb to existing TB
drugs (Figure 2). We observed a clear structure−activity
relationship, indicating that the compounds acted on a specific
target or targets. The TB agents that exhibited synergy with
these 6-azasteroids utilize a wide array of killing mechanisms,
disrupting processes ranging from cell-wall biosynthesis to
ATP biosynthesis (Table 1).
We found that genes involved in cholesterol catabolism were
not required for the activity of 6-azasteroid 4a (Table 2),
despite our previous work demonstrating that 6-azasteroids,
including 4a, inhibit the first enzyme in the catabolic pathway,
3β-hydroxysteroid dehydrogenase (hsd),19 and a body of
evidence indicating that cholesterol catabolism is important for
Table 2. Mce3R Regulon Is Required for Azasteroid 4a
Activitya
aThe data shown are representative of at least two independent
biological replicates and were performed in technical triplicate. bWith
cholesterol or glycerol as a carbon source, the indicated strain of Mtb
in 7H9 medium was incubated with 20 μM 4a or DMSO control and
INH at various concentrations (2-fold dilutions) for 14 days at 37 °C.
cWith glycerol as a carbon source, the indicated species of
mycobacteria in 7H9 medium was incubated with 20 μM 4a or
DMSO control and INH or BDQ at various concentrations (2-fold
dilutions) for 4−7 days at 37 °C. dThe drug concentration at which
no growth occurred was recorded as the drug MIC. MIC values are
shown in Table S1B. The ratio of the drug MIC in the presence of 4a
to the MIC of INH or BDQ alone was determined. Ratios of 0.0625−
0.125 are indicated with green shading and reflect potentiation. Ratios
of >0.125 and ≤0.5 are indicated with orange shading and reflect low
potentiation due to low activity of INH against M. marinum. Ratios
>0.5 are indicated with red shading and reflect no change in MIC.
Table 3. Frequencies of in Vitro Spontaneous Resistance to
6a and BDQa
frequency of resistanceb
BDQ (20 μM) BDQ (10 μM) BDQ (0 μM)
6a (400 μM) 7.8 × 10−8 ND 1.1 × 10−7
6a (200 μM) ND 2 × 10−7 3.6 × 10−6
6a (0 μM) 5.5 × 10−9 3.4 × 10−7
aCDC1551 Mtb was plated on 7H11 medium supplemented with
10% OADC containing the indicated concentration of drug(s).
Resistant mutants were counted after 3−4 weeks. ND = not detected.
bMutations per cell division.
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Mtb persistence and survival in a mouse model of infection.1,2
Moreover, the 6-azasteroids were active against Mtb grown on
a sugar carbon source, glycerol, as well as against Mtb grown
on a cholesterol carbon source (Figure 2). Importantly, 6-
azasteroids 4a and 6a were active under low-oxygen growth
conditions. Taken together, the evidence suggests that 6-
azasteroids act on a target that contributes to drug tolerance
regardless of carbon source or oxygen level.
Transcriptional,2 phenotypic,34 and biochemical profiling22
have identified genes outside the Mtb cholesterol catabolism
gene cluster that are regulated by cholesterol, that are
important for growth on cholesterol in vitro, or that have
cholesterol-specific structural motifs. Several of these genes are
found within a TetR-like transcriptional regulon controlled by
the Mce3R repressor.26,27 Transposon disruption of mce3R
significantly inhibits growth of Mtb on cholesterol.34 However,
the genes within the Mce3R regulon are not required for
catabolism of cholesterol,8,9 suggesting that these genes have
an alternate role inMtb survival. Therefore, we investigated the
importance of four genes in the Mce3R regulon ( fadE18,
echA13, melF, and melH) in 6-azasteroid activity. Intriguingly,
fadE18, melF, and melH were required for 6-azasteroid
potentiation of INH activity. Although echA13, annotated to
encode an enoyl-CoA hydratase, was not required, the Mtb
genome encodes many other enoyl-CoA hydratases that might
compensate for disruption of this gene.
The precise biochemical functions of the proteins encoded
in the Mce3R regulon have yet to be established. However,
bioinformatics and phenotypic assays allow for tentative
assignment of their function. The fadE17, fadE18, and mel2
genes are important contributors to Mtb resistance to various
cellular stresses. The entire Mce3R locus is present in
M. marinum and provides resistance to reactive oxygen species
and reactive nitrogen species.24 Significantly, the Mce3R
regulon is absent in saprophytic mycobacteria,28 which
suggests that the primary role of the regulon is mediating
host-derived stresses, such as those encountered by Mtb in
activated macrophages. Consistent with this observation, the
mel2 operon is required for persistence and dissemination of
Mtb infection in mice.35
The fadE17 and fadE18 genes encode an acyl-CoA
dehydrogenase with an unusual α2β2 heterotetrameric that is
characteristic of acyl-CoA dehydrogenases that oxidize
cholesterol-derived substrates.22 The melF and melH genes
reside in a single operon (Rv1936-Rv1941) of the mel2 locus,
which encodes homologues of the Lux luminescence system.
This system catalyzes formation of a fatty acid aldehyde by
means of an ATP-dependent process.
The mel2 operon is thought to provide resistance to
oxidative stress, which is consistent with the idea that the
operon encodes catalytic machinery to generate a fatty acid
aldehyde that can remove oxidizing species from the cellular
milieu.24 When Mtb production of ergothioneine, which is a
redox couple in Mtb, is disrupted, fadE18 is up-regulated.36
When Mtb is exposed to a lysosomal soluble fraction prepared
from activated macrophages, both fadE17 and fadE18 are
induced.37 In addition, a recent study has shown that cysteine
in combination with INH or rifampin can enhance oxygen
consumption by Mtb, thereby leading to increased production
of reactive oxygen species and sterilization of Mtb cultures.38
Upon addition of cysteine to INH-treated Mtb cultures, the
transcription level of fadE18 increases nearly 4-fold. Treatment
of Mtb with BDQ for 48−96 h results in up-regulation of mel2
genes, especially melF, which is up-regulated about 8-fold.32
These responses indicate that the Mce3R regulon plays a
critical role in the Mtb response to oxidative, host-induced, or
drug-induced stress.
In contrast to treatment with INH, rifampin, or BDQ,
treatment with 6-azasteroid 4a or 6a for 6 h resulted in 3- to 4-
fold down-regulation of the Mce3R-regulated echA13-fadE17-
fadE18 operon. Although the transcription levels of mel2 genes
were unchanged or only marginally changed after 6 h of 6-
azasteroid treatment, the response of the mel2 gene to BDQ
treatment is likely to be indirect, given the long post-BDQ
treatment time (48−96 h) at which up-regulation is
observed.32 Together with our mutant experiment in which
fadE18 was required for 6-azasteroid potentiation, the evidence
supports a mechanism in which the 6-azasteroids suppress
fadE18/Mce3R-dependent activation of a drug-induced stress-
resistance pathway.
Figure 5. Differentially expressed transcripts as analyzed by RNA-seq
are visualized in heatmaps. The transcriptional profiles of Mtb strains
CDC1551 (WT), ASR1, and ASR2 exposed for 6 h to 4a (30 μM) or
6a (30 μM) were compared with the profile of the corresponding
untreated group. Gene names are indicated to the right of the
heatmap, and strains and treatment conditions are shown on the
bottom. The color scales represent log2-fold changes in gene
expression in treated groups relative to expression in untreated
groups; each colored cell represents the mean of biological triplicates.
Red, blue, and black lines denote the echA13-fadE17-fadE18, mel2,
and mce3 operons, respectively.
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Mtb spontaneous resistant mutants that were raised against
6a showed a thinner, almost transparent cell-wall phenotype
and were difficult to culture. Importantly, we found that
Mce3R genes were not directly involved in spontaneous
resistance to the 6-azasteroid. Among the genes where
nonsynonymous mutations occurred in the resistant mutants,
PE/PPE genes were not investigated further as candidates for
involvement in the azasteroid-resistance phenotype, because of
their high variability in Mtb. In addition, it is unlikely that
genes involved in PDIM biosynthesis are directly involved in
the azasteroid-resistance phenotype, because the loss of PDIM
production is commonly observed during in vitro propagation
of Mtb cultures.39 The remainder of the mutations identified
were in genes involved in mycobacterial cell-wall synthesis and
efflux systems, which is consistent with a mechanism of
resistance that decreases 6-azasteroid uptake, and simulta-
neously, the growth fitness of Mtb is reduced.
In addition to suppressing Mce3R genes, 6-azasteroids also
suppressed the expression of genes in the DosR,40 PhoP/R,33
and SigB regulons41 and in the icl1 operon.42 All these genes
are involved in Mtb stress resistance and the establishment of
persistence. There is evidence that inhibitors of DosR genes
also increase the activity of INH,43 although the increase is not
as dramatic as that observed for 6-azasteroids. This enhance-
ment of INH activity by the 6-azasteroids indicates that they
inhibit a network of Mtb stress resistance and that the
disruption of this network leads to the potentiation of TB
drugs.
Codrug sensitization is emerging as a useful strategy for
treating TB, including multidrug-resistant TB.44−47 Variations
on this strategy include targeting specific drug-activation
pathways46 as well as more general drug-desensitization targets
such as the DosRST regulon43 and thiol stress.47 Thus, these
drug-sensitization strategies are a powerful tool for killing
resilient and/or nonreplicating Mtb.
In summary, our work further supports the idea that Mce3R-
regulated genes are important for managing the Mtb cellular
response to drug-induced stress (Figure 6). Moreover, our
findings suggest that Mtb depends on cholesterol or its
metabolites for activation of stress resistance through the
Mce3R regulon (Figure 6). Our discoveries that 6-azasteroid
suppression of drug tolerance depends on Mce3R-regulated
genes and occurs under low-oxygen conditions present an
intriguing avenue for further development of codrugs that can
improve the efficacy of existing TB drugs in vivo.
■ MATERIALS AND METHODS
Synthesis of 6-Azasteroid Precursor 1 and the
Corresponding 17β-Carboxylic Acid. 17β-Carbomethoxy-
6-t-butoxycarbonyl-6-azaandrost-4-en-3-one (1) was synthe-
sized as reported previously16−18 and then converted to 17β-
carboxy-6-t-butoxycarbonyl-6-azaandrost-4-en-3-one as de-
scribed in the literature.17 Both compounds were assessed to
be greater than 95% pure by 1H NMR spectroscopy.
General Procedure for Coupling Amines to the 17β-
Carboxylic Acid and Subsequent Deprotection of the
Ring Nitrogen.17 17β-Carboxy-6-t-butoxycarbonyl-6-azaan-
drost-4-en-3-one (30 mg) was suspended in 1 mL of toluene.
One drop of DMF and 15 μL of pyridine were added to the
solution, which was then cooled in an ice bath, treated with 10
μL of thionyl chloride, and stirred for 1 h. The solution was
filtered, and the filtrate was concentrated. The resulting acid
chloride residue was dissolved in DCM (5 mL) and treated
with the desired amine to give amide 3. Amide 3 was dissolved
in DCM (1 mL) and treated with 2 mL of TFA at 20 °C to
remove the BOC protecting group from the ring nitrogen.
After 2 h, the reaction mixture was poured into saturated
NaHCO3 solution; the layers were separated, and the organic
layer was washed with brine and dried over Na2SO4.
Chromatography using 5% (v/v) MeOH in DCM provided
deprotected amide 4.
Procedure for N6 Alkylation of Deprotected Amides
4a and 4b.8,18 Amides 4a and 4b (30 mg) were dissolved
separately in THF (5 mL) and treated with 1.2 equiv of NaH.
After stirring for 30 min at 20 °C, the reaction mixture was
treated with the desired iodoalkane (1 equiv) for a further 30
min. When the reaction was complete as judged by TLC
(approximately 5 h), 30 mL of EtOAc was added, and the
resulting solution was washed with water and brine (3× each)
and dried over Na2SO4. Chromatography using 5% (v/v)
MeOH in DCM provided N6-alkylated amides 5a, 6a, 6b, and
7a. For the synthesis of 8a, amide 4a (30 mg) was dissolved in
DMF and treated with 3 equiv of NaH. After 30 min at 20 °C,
5 equiv of iodomethane was added into the reaction, followed
by stirring at 20 °C for 2 h to give compound 8a. Active
azasteroids 4a, 5a, 6a, 8a, and 3c were resynthesized for
verification and were determined to be greater than 99% pure
by LC-MS.
Bacterial Strains and Culture Conditions. Mutant and
complemented strains used in this study and their sources are
listed in Table S2. Mtb strains CDC1551, H37Rv, and
H37Rv(mlux), also known as H37Rv(pFCA-luxABCDE),
were used as wild-type strains for this study. Mtb strains
were cultured at 37 °C either in Middlebrook 7H9 medium
(broth) supplemented with 0.2% glycerol or 0.1 mM
cholesterol, 0.5% BSA, 0.08% NaCl, and 0.05% (v/v) tyloxapol
(7H9/glycerol or 7H9/cholesterol medium) or on 7H11
medium (agar) supplemented with 10% oleate-albumin-
dextrose-NaCl (OADC), 0.5% glycerol, and 0.05% Tween 80.
Determination of MICs.MICs were determined by means
of a broth microdilution assay.48 Briefly, cells were grown to
mid log phase and then diluted 1000-fold in defined media.
The cell suspension was added to a 96-well plate containing
compound dilutions to obtain a final volume of 100 μL. Plates
were incubated at 37 °C for 14 days, and MICs were
determined as the lowest concentration that resulted in
complete inhibition of growth by visual inspection or
luminescence readouts (mlux). For isobolograms, 5-fold serial
Figure 6. Efficacy of 6-azasteroids requires Mce3R-regulated genes.
Genes in the Mce3R regulon are required for 6-azasteroid
antimycobacterial activity. Cholesterol transcriptionally regulates the
Mce3R genes,2 and this regulon is repressed by Mce3R, a tetR-like
repressor protein.
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dilutions of INH or BDQ were used so that the concentration
range in a single plate was sufficient. If the 90% reduction in
RLU could not be determined directly, a linear interpolation
between two RLU values was used to determine the
concentration at 90% inhibition.
LORA.49 A low-oxygen-adapted culture of H37Rv(mlux)
Mtb expressing a luciferase was used for the LORA.
H37Rv(mlux) Mtb stored at −80 °C (1 × 105 CFU/mL)
was thawed and exposed to 2-fold or 3-fold serial dilutions of
test compound diluted in 7H12 broth in black 96-well plates,
which were incubated for 10 days at 37 °C in an anaerobic jar
under hypoxic conditions created with an Anoxomat system
(MART Microbiology). Luminescence readouts were obtained
after 28 h of normoxic recovery in 5% CO2. To calculate the
MIC, the dose response curve was plotted as percentage
growth and fitted to the Gompertz model. The MIC was
defined as the lowest concentration inhibiting recovery of the
luminescence signal by 90% relative to bacteria-only controls.
FIC is defined as the ratio of the MIC of the inhibitor when
used in combination to the MIC of the inhibitor alone. The
FIC index is the sum of the FICs for the two drugs used. The
minimum concentrations that worked in combination were
used. The determination of drug MICs for rifampin, INH,
linezolid, pretomanid, and BDQ were conducted as positive
controls.
LORA Time-Kill Assay. The low-oxygen-adapted Mtb
strain H37Rv(mlux) was cultured as described above for the
LORA. Compounds 4a and 6a were tested at 10 μM in
combination with BDQ at 0.5, 0.25, 0.15, 0.0625, and 0.05 μM.
At 0, 7, and 10 days, cultures were recovered in an aerobic
environment (5% CO2) for 28 h and then were serially diluted
in 7H9 broth and plated on 7H11/OADC agar plates. Drug
concentration is diluted at least 300-fold. Plates were incubated
at 37 °C, and CFUs were counted after 3−4 weeks. The limit
of detection is 10 CFU/mL. Statistical analysis was done using
an unpaired Student’s t-test (GraphPad Prism 4).
Aerobic Time-Kill Assay. Mtb was grown at 37 °C to mid
log phase and then diluted in fresh medium to 5 × 105 CFU/
mL. Test compounds were added at defined concentrations.
Aliquots of cultures were withdrawn at specified time points,
and either OD (600 nm) (CDC1551) or luminescence (mlux)
was recorded. At 0, 2, and 7 days, aliquots of cultures were
serially diluted in 7H9 broth and plated on 7H11/OADC agar
plates. Drug concentration is diluted at least 300-fold. Plates
were incubated at 37 °C, and CFUs were counted after 3−4
weeks. The limit of detection is 10 CFU/mL.
Frequency of Resistance. Mtb mutants resistant to 6a
were isolated by means of the procedure reported by Ioerger et
al.50 H37Rv Mtb bacteria were grown at 37 °C to mid log
phase and then diluted in fresh Middlebrook 7H9 medium
containing ADC-Tween 80 to 5 × 108 CFU/mL. Middlebrook
7H11/OADC agar plates with 6a at 200 or 400 μM with or
without 10 or 20 μM BDQ were inoculated with 108, 107, 106,
and 105 CFU/plate, and the plates were incubated at 37 °C for
3−4 weeks. Resistance was tested by measuring the MICs of
6a, BDQ, and INH. The frequency of the appearance of
resistant mutants was calculated.
Whole Genome Sequencing. Mtb strains CDC1551,
ASR1, ASR2, and ASR3 were grown to log phase, and their
genomes were extracted with cetyltrimethylammonium bro-
mide and lysozyme as described in the literature.51 Whole
genome preparation, sequencing, assembly, and pairwise
analysis were performed as previously described.52 Briefly,
DNA was sheared into ∼20 000 bp fragments using Covaris G-
tube spin columns and was end-repaired before being ligated to
SMRTbell adapters (Pacific Biosciences). The resulting library
was treated with an exonuclease cocktail to remove unligated
DNA fragments and was size-selected on a Sage Science
BluePippin system to obtain fragments of ≥7000 bp. The P5−
C3 sequencing enzyme and chemistry were used to sequence
the resulting libraries on the Pacific Biosciences (PacBio) RS II
platform. Resulting PacBio sequencing data were assembled
using HGAP3 (ver. 2.2.0). For Illumina sequencing, genomic
DNA (1 μg) was sheared to achieve ∼200 bp fragments using
a Bioruptor Pico sonicator (Diagenode). Library preparation
was performed using the end repair, A-tailing, and adaptor
ligation NEBNext DNA library prep modules for Illumina from
New England Biolabs, according to the manufacturer’s
protocol. The resulting libraries were sequenced on the
Illumina HiSeq 2500 platform. Illumina reads were then
mapped to the curated PacBio assemblies using samtools
mpileup53 to correct PacBio sequencing errors. Genome
circularization, curation, and annotation were performed with
a custom postassembly pipeline (https://github.com/
powerpak/pathogendb-pipeline).52 Finally, NUCmer (ver.
3.1)54 was used for aligning mutant genome strains to the
PS00103 reference genome to identify genetic variants. Whole
genome sequencing data are available in the NCBI BioProject
database under accession number PRJNA482894.
RNA-seq Transcriptional Profiling and qRT-PCR. Mtb
strains CDC1551, ASR1, and ASR2 were grown to OD ∼ 0.6
and treated with 30 μM 4a or 6a or with vehicle control for 6 h
in Middlebrook 7H9 medium supplemented with 0.2%
glycerol, 0.5% BSA, 0.08% NaCl, and 0.05% (v/v) tyloxapol.
Total RNA was extracted using TriZol, with chloroform back
extraction and 70% ethanol precipitation. RNA was purified
with an RNeasy kit (Qiagen) with DNase treatment. Total
RNA was processed for ribosomal reduction library con-
struction. Libraries were sequenced as single-end 75 bp reads
on an Illumina NextSeq500 sequencer following the
manufacturer’s protocols (Cofactor Genomics, Inc.). The
sequence reads were aligned to the CDC1551 Mtb complete
genome (The National Center for Biotechnology Information
Database) using STAR (https://github.com/alexdobin/
STAR). For each transcript or patch, the reads per kilobase
million (RPKM) expression value was calculated for each
sample. For each replicate group, the mean and coefficient of
variation for each transcript or patch were calculated across the
expression values for the samples in that group. These means
were considered to be the expression values for the replicate
group. P-values were calculated for comparisons between the
means of each pair of replicate groups using a Welch’s t-test
corrected for false discovery rate by means of the Benjamini−
Hochberg procedure. For each comparison, differentially
expressed genes were identified as genes with an average
normalized count of >100, differential gene expression of >2-
fold, and a P-value of <0.05. Three biological replicates were
performed. RNA-seq data are available in the NCBI GEO
database under accession number GSE118482. Total RNA was
reverse-transcribed using PrimeScript RT Master Mix
(TaKaRa Bio). The resulting cDNA was used for PCR
amplification using iTaq Universal SYBR Green Supermix
(Bio-Rad). Relative level of gene expression was calculated by
the ΔΔCq method with 16s rRNA as an internal control.
Primers are listed in Table S3.
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